HROW Harrow, Inc.
Mergers ·
Harrow paid about $4.3 million in cash to close its purchase of Melt Pharmaceuticals on Nov 17, 2025. The contingent milestone payments are unchanged, and the MELT-300 sedation drug still needs an NDA, which the company plans for the first half of 2027.
Harrow says it needs more time for accounting analyses and its internal controls evaluation. It expects no changes to preliminary 2024 results, including revenues of between $198 million and $200 million.
Harrow is a provider of ophthalmic disease management solutions in North America, offering FDA-approved eye care products to U.S. eyecare professionals. Its branded products include IHEEZO, a chloroprocaine ophthalmic gel for ocular surface anesthesia; VEVYE, a cyclosporine ophthalmic solution for dry eye disease that uses a water-free vehicle; TRIESENCE, a triamcinolone injectable suspension; VIGAMOX, a moxifloxacin eye drop for bacterial conjunctivitis; ILEVRO, a nepafenac eye drop for pain and inflammation associated with cataract surgery; and FLAREX, a corticosteroid eye suspension. Its biosimilars include BYOOVIZ, the first FDA-approved LUCENTIS biosimilar, which the company expects to launch in mid-2026, and OPUVIZ, an FDA-approved EYLEA biosimilar, which it expects to launch in mid-2027. BYQLOVI, a high-potency ophthalmic corticosteroid for post-operative inflammation and pain after ocular surgery, is also expected to launch in mid-2026. The company says its branded product investments focus primarily on the U.S. and Canadian markets.
| Product or program | What it is | Stage |
|---|---|---|
| IHEEZO | Chloroprocaine ophthalmic gel for ocular surface anesthesia | |
| VEVYE | Cyclosporine ophthalmic solution for dry eye disease | |
| BYOOVIZ | Ranibizumab-nuna biosimilar for wet AMD and other retinal conditions | FDA-approved |
| OPUVIZ | Aflibercept-yszy biosimilar for wet AMD and diabetic macular edema | FDA-approved |
| BYQLOVI | High-potency ophthalmic corticosteroid for post-operative inflammation and pain |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $272.3 million | $199.6 million |
| Research and development | $20.9 million | $12.2 million |
| Net income (loss) | -$5.1 million | -$17.5 million |
| Cash from operations | $43.9 million | -$22.2 million |
| Cash and equivalents | $72.9 million | $47.2 million |
Harrow, Inc. trades under the ticker HROW on NASDAQ.
Harrow, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Harrow, Inc. is 1360214. Its filings are on SEC EDGAR.
37,487,850 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-10.
Our directory records Harrow, Inc. under United States.
Our directory classifies Harrow, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Harrow, Inc. is US4158581094.
aibio.space lists Harrow, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Harrow is a provider of ophthalmic disease management solutions in North America, offering FDA-approved eye care products to U.S. eyecare professionals. Its branded products include IHEEZO, a chloroprocaine ophthalmic gel for ocular surface anesthesia; VEVYE, a cyclosporine ophthalmic solution for dry eye disease that uses a water-free vehicle; TRIESENCE, a triamcinolone injectable suspension; VIGAMOX, a moxifloxacin eye drop for bacterial conjunctivitis; ILEVRO, a nepafenac eye drop for pain and inflammation associated with cataract surgery; and FLAREX, a corticosteroid eye suspension.
IHEEZO: Chloroprocaine ophthalmic gel for ocular surface anesthesia
VEVYE: Cyclosporine ophthalmic solution for dry eye disease
$272.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Harrow, Inc. reported a net loss of $5.1 million for the fiscal year ended Dec 31, 2025, and generated $43.9 million of cash from operations, per its annual report to the SEC.
$20.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,8.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,8.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio